000			01940cam a2200253 4500500
005			20260503024200.0
041			_afre
042			_adc
100	1	0	_aArmi, Sara _eauthor
700	1	0	_aTailliar, Maxence _eauthor
700	1	0	_aVial, Romain _eauthor
700	1	0	_aBobot, Mickaël _eauthor
700	1	0	_aBrunet, Philippe _eauthor
700	1	0	_aBurtey, Stéphane _eauthor
700	1	0	_aSallée, Marion _eauthor
700	1	0	_aRobert, Thomas _eauthor
700	1	0	_aLefèvre, Flora _eauthor
245	0	0	_aBack matter
260			_c2026.
500			_a57
520			_aWe report two cases of complete remission of uremic calciphylaxis in hemodialysis patients despite continued use of vitamin K antagonists (VKAs). These cases highlight the potential of a multimodal treatment approach including rheopheresis as a promising therapy when VKA discontinuation is not feasible. Both patients presented with severe calciphylaxis while on VKAs for mechanical mitral valve replacement. They received intensive multimodal treatment, including daily hemodialysis, intravenous sodium thiosulfate, calcimimetics, phosphate binders, opioid analgesics, and plastic surgery evaluation. In addition, rheopheresis was initiated twice weekly for four months, during which VKAs were maintained. Rheopheresis frequency was then gradually reduced. Complete wound healing was achieved within seven months. Both patients subsequently underwent parathyroidectomy for tertiary hyperparathyroidism. To our knowledge, these are the first reported cases of full remission of calciphylaxis without VKA discontinuation. A multimodal, multidisciplinary treatment strategy may represent an effective approach for high-risk anticoagulated patients.
786	0		_nNéphrologie & Thérapeutique | 22. | 1 | 2026-04-03 | p. 76-76 | 1769-7255
856	4	1	_uhttps://stm.cairn.info/journal-nephrologie-et-therapeutique-2026-1-page-76?lang=en&redirect-ssocas=7080
999			_c2228150 _d2228150